演題詳細

ポスター / Poster

ポスター 23 (Poster 23) :低悪性度B細胞リンパ腫:ベンダムスチン

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
瀧本 理修 (Rishu Takimoto):1
1:札幌医科大学医学部附属病院 腫瘍・血液内科
 
前へ戻る

Treatment of relapsed/refractory indolent lymphoma with bendamustine.Our experience and perspective

演題番号 : PS-1-171

熊野 義久 (Yoshihisa Kumano):1、本宮 佳奈 (Kana Motomiya):1、彼谷 裕康 (Hiroyasu Kaya):1、奥村 廣和 (Hirokazu Okumura):1

1:Hematology, Toyama Prefectural Central Hospital, Japan

 

Background:We retrospectively analyzed efficacy and toxicity of bendamustine alone or in combination with Rituximab for relapsed/refractory indolent B-cell lymphoma in our institute.
Patients and Methods:Between May 2011 and March 2013,20 patients(11 men and 9 women with median age of 56.5:40-86) were received bendamustine alone or in combination with Rituximab. Histology included follicular lymphoma(n=11),mantle cell lymphoma(n=2),lymphoplasmacytic lymphoma(n=3),marginal zone lymphoma(n=4).9 patients were received single-agent bendamustine at a dose of 120mg/sqm,11 patients were received bendamustine at a dose of 90mg/sqm with rituximab(375mg/sqm).
Results:14 patients achieved CR+CRu,5 patients achieved PR. Median PFS was 9 months and median OS was 10 months.3 patients with follicular lymphoma received consolidation treatment with 90Y-Ibritumomab tiuxetan(n=2) or allogeneic stem cell transplantation(n=1).All of them achieved CR and they are alive with progression free.
Conclusions:Bendamustine is effective and tolerable in relapsed/refractory indolent B-cell lymphoma.Consolidation with 90Y-Ibritumomab tiuxetan or allogeneic stem cell transplantation after bendamustine will be a useful option for these patients.

前へ戻る